{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:12:59Z","timestamp":1794607979619,"version":"4.9.1"},"reference-count":107,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Galapagos","id":[{"id":"https:\/\/ror.org\/04e4j5d46","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Janssen"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Boehringer-Ingelheim"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"DOI":"10.1093\/rheumatology\/key276","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T07:13:12Z","timestamp":1536822792000},"page":"i43-i54","source":"Crossref","is-referenced-by-count":278,"title":["JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis"],"prefix":"10.1093","volume":"58","author":[{"given":"George E","family":"Fragoulis","sequence":"first","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Siebert","sequence":"additional","affiliation":[{"name":"Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"key\n\t\t\t\t2019022610403430900_key276-B1","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: what can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B3","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72(Suppl 2)","author":"O\u2019Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of Janus Kinase inhibitors in inflammatory bowel disease","volume":"11","author":"De Vries","year":"2017","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B7","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1136\/annrheumdis-2016-211046","article-title":"Regulatory role of the JAK STAT kinase signalling system on the IL-23\/IL-17 cytokine axis in psoriatic arthritis","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/exd.12265","article-title":"Jakpot! New small molecules in autoimmune and inflammatory diseases","volume":"23","author":"Ghoreschi","year":"2014","journal-title":"Exp Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3899\/jrheum.150636","article-title":"Ex vivo signaling protein mapping in T lymphocytes in the psoriatic arthritis joints","volume":"93","author":"Fiocco","year":"2015","journal-title":"J Rheumatol Suppl"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/BOR.0000000000000399","article-title":"Janus kinase\/signal transducer and activator of transcription pathways in spondyloarthritis","volume":"29","author":"Raychaudhuri","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B12","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clim.2010.05.003","article-title":"Analysis of JAK2 and STAT3 polymorphisms in patients with ankylosing spondylitis in Chinese Han population","volume":"136","author":"Chen","year":"2010","journal-title":"Clin Immunol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B15","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/ard.2010.133322","article-title":"Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese","volume":"70","author":"Davidson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B16","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B17","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych","year":"2018","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican","year":"2005","journal-title":"Mediators Inflamm"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.jid.5700008","article-title":"Keratinocyte apoptosis in epidermal development and disease","volume":"126","author":"Raj","year":"2006","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B20","doi-asserted-by":"crossref","first-page":"e12555","DOI":"10.1111\/dth.12555","article-title":"Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors","volume":"30","author":"Wcis\u0142o-Dziadecka","year":"2017","journal-title":"Dermatol Ther"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B21","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/jid.2009.25","article-title":"Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690, 550 in patients with psoriasis","volume":"129","author":"Boy","year":"2009","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690, 550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B23","first-page":"252","article-title":"Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions","volume":"13","author":"Menter","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B25","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jaad.2016.01.013","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study","volume":"74","author":"Papp","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B28","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/jdv.13702","article-title":"Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study","volume":"30","author":"Valenzuela","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B29","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B31","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B35","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B36","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B37","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.autrev.2016.03.008","article-title":"Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies","volume":"15","author":"Gilhar","year":"2016","journal-title":"Autoimmun Rev"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B38","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B39","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B40","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B42","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamadermatol.2015.3772","article-title":"Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis","volume":"152","author":"Dhayalan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","article-title":"Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients","volume":"78","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B45","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B47","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/1203475417716363","article-title":"A case of topical ruxolitinib treatment failure in alopecia areata","volume":"21","author":"Deeb","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B48","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B49","first-page":"e24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B51","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B53","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B54","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B55","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B56","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B57","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.gtc.2017.05.015","article-title":"Janus Kinase antagonists and other novel small molecules for the treatment of Crohn\u2019s disease","volume":"46","author":"Boland","year":"2017","journal-title":"Gastroenterol Clin North Am"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mrfmmm.2010.01.017","article-title":"Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT\u2013JAK pathway, susceptibility to DNA damage and Crohn\u2019s disease in a New Zealand population","volume":"690","author":"Ferguson","year":"2010","journal-title":"Mutat Res"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B59","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ng.717","article-title":"Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci","volume":"42","author":"Franke","year":"2010","journal-title":"Nat Genet"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies","volume":"17","author":"Kim","year":"2017","journal-title":"Immune Netw"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaut.2017.07.004","article-title":"Novel therapeutic targets for inflammatory bowel disease","volume":"85","author":"Argollo","year":"2017","journal-title":"J Autoimmun"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B62","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B63","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B64","doi-asserted-by":"crossref","first-page":"S1308","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 (Upadacitinib), an oral Jak1 Inhibitor, as induction therapy in patients with Crohn\u2019s Disease: results from Celest","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gatroenterology"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B65","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B66","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ecco-jcc\/jjx133","article-title":"Tofacitinib in patients with ulcerative colitis: health-related quality of life in phase 3 randomised controlled induction and maintenance studies","volume":"12","author":"Pan\u00e9s","year":"2018","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev-med-050715-104506","article-title":"The type I interferonopathies","volume":"68","author":"Lee-Kirsch","year":"2017","journal-title":"Annu Rev Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B69","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B70","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B71","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"138","author":"Fr\u00e9mond","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B72","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/annrheumdis-2016-209841","article-title":"Familial chilblain lupus due to a gain-of-function mutation in STING","volume":"76","author":"K\u00f6nig","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B73","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jid.2016.02.015","article-title":"JAK1\/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus","volume":"136","author":"Wenzel","year":"2016","journal-title":"J Invest Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B74","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1136\/annrheumdis-2016-210565","article-title":"Response to: \u2018JAK inhibition in STING-associated interferonopathy\u2019 by Crow et al","volume":"75","author":"T\u00fcngler","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B76","first-page":"2536","article-title":"Evaluation of JAK inhibition with topical tofacitinib in an experimental autoimmune uveitis model (EAU)","volume":"54","author":"Huang","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B77","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/14656566.2017.1361408","article-title":"Small molecules as therapy for uveitis: a selected perspective of new and developing agents","volume":"18","author":"Pleyer","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B78","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1161\/CIRCULATIONAHA.117.030423","article-title":"Inhibition of JAK\u2013STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis","volume":"137","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B79","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B80","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B81","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B82","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B83","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B84","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","article-title":"Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis","volume":"75","author":"Wu","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B85","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B86","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B87","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/rheumatology\/kew329","article-title":"Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies","volume":"56","author":"Schulze-Koops","year":"2017","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B88","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/annrheumdis-2017-eular.1335","article-title":"FRI0092 Effects of baricitinib on haemoglobin and related laboratory parameters in rheumatoid arthritis patients","volume":"76","author":"Kay","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B89","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3899\/jrheum.161161","article-title":"Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis","volume":"45","author":"Keystone","year":"2018","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B90","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B91","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B92","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2017-212461","article-title":"Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies","volume":"77","author":"Taylor","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B93","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/art.40054","article-title":"Peficitinib, a JAK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B94","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.39955","article-title":"Peficitinib, a JAK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate","volume":"69","author":"Kivitz","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B95","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B96","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.39463","article-title":"Decernotinib: a next-generation jakinib","volume":"68","author":"Gadina","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B97","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B98","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1124\/dmd.116.071100","article-title":"VX-509 (decernotinib)-mediated CYP3A time-dependent inhibition: an aldehyde oxidase metabolite as a perpetrator of drug\u2013drug interactions","volume":"44","author":"Zetterberg","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B99","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B100","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B101","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B102","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/annrheumdis-2016-210105","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2","volume":"76","author":"Kavanaugh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B103","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B104","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2016-210104","article-title":"Filgotinib (GLPG0634\/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1","volume":"76","author":"Westhovens","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B105","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B106","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/annrheumdis-2016-209330","article-title":"Tofacitinib for polyarteritis nodosa: a tailored therapy","volume":"75","author":"Rimar","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019022610403430900_key276-B107","doi-asserted-by":"crossref","DOI":"10.1016\/j.hemonc.2017.07.002","article-title":"Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report","author":"Sin","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/Supplement_1\/i43\/27984844\/key276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T01:21:31Z","timestamp":1751851291000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/Supplement_1\/i43\/5365419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":107,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2019,2,26]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key276","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}